Skip to main content

Coronavirus: Medical Treatments

Question for Department of Health and Social Care

UIN 45746, tabled on 2 September 2022

To ask the Secretary of State for Health and Social Care, what action he is taking to increase rapid patient access to anti-viral treatments for covid-19.

This answer is the replacement for a previous holding answer.

Answered on

27 September 2022

Currently, immunocompromised patients, who form part of the high-risk cohort are a priority group eligible for receiving novel effective COVID-19 treatments within the community following a positive test. These treatments include both antiviral drugs and neutralising monoclonal antibodies which are available via COVID Medicines Delivery Units.

The Therapeutics Clinical Review Panel has been established to review the patient cohorts which could be eligible for COVID-19 therapies. On 30 May 2022 the Department published an Independent Advisory Group report which revised the high-risk cohort and included additional groups of patients. As a result of these changes and improved identification by the National Health Service, the cohort of eligible patients has grown to an estimated 1.8 million patients in the United Kingdom.

Access to treatments could be extended further if evidence from clinical trials supports doing so. The PANORAMIC study which aims to improve understanding of the effectiveness antivirals in preventing hospitalisation and/or death in a largely vaccinated population. It will provide data for the NHS to determine which patient groups could benefit most from antiviral treatments.

Named day
Named day questions only occur in the House of Commons. The MP tabling the question specifies the date on which they should receive an answer. MPs may not table more than five named day questions on a single day.